GRAL | Ticker Profile - Titan Protect

GRAL

GRAIL, Inc.

Healthcare · Diagnostics & Research · NMS

$59.98

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$3.1B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-7.78

Based on estimated future earnings — lower means cheaper

Rev Growth

+28.1%

Year-over-year revenue change

Profit Margin

-253.2%

How much profit the company keeps from each dollar of revenue

ROE

-16.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$69.00

+15% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 7 analysts covering this stock

About GRAIL, Inc.

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

https://grail.com

Country: United States Employees: 910 Industry: Diagnostics & Research

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

1.365

Excellent risk-adjusted returns

Kelly Fraction

0.1089

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

2.191

Returns exceed worst-case losses — strong risk profile

Annual Return

137.9%

Historical annualised return based on price data

Max Drawdown

-62.9%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$118.84

50% below the year high

52W Low

$29.95

100% above the year low

Avg Volume

789,803

Average daily shares traded — higher means easier to buy and sell

Short Ratio

12.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

16.9%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-10.30

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

2.04

Heavy leverage — higher financial risk if revenues decline

Current Ratio

11.74

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

11.29

Like current ratio but excludes inventory — stricter test

Gross Margin

49.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-332.9%

Profit from core operations before interest and tax

Free Cash Flow

$-107,751,872

Negative — the business is spending more than it generates

Revenue (TTM)

$156M

Total revenue over the last 12 months

Net Income

$-395,324,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$80.00

Target Median

$69.00

Target Low

$56.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go